EMEA-002387-PIP02-21
Key facts
| Invented name |
Nexpovio
|
| Active substance |
Selinexor
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0364/2021
|
| PIP number |
EMEA-002387-PIP02-21
|
| Pharmaceutical form(s) |
Tablet
|
| Condition(s) / indication(s) |
Treatment of endometrial carcinoma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Karyopharm Europe GmbH
E-mail: cnippgen@karyopharm.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|